This Phase II study was designed as an open-label, randomized, multicenter study evaluating weekly administration of OGX-011 in combination with second-line chemotherapy. According to data the primary objectives of safety and tolerability were achieved in the 42 patients evaluated in the study. Additionally, patients treated with second-line chemotherapy plus OGX-011 showed ongoing survival durations better than results published with chemotherapy alone.
Fred Saad, primary investigator in the study, said: “The data suggests that retreatment with docetaxel when combined with OGX-011 may reverse chemotherapy resistance in second-line docetaxel retreatment. We look forward to confirming these data in planned Phase III studies.”